The Gel Is Not Sterile: Twelve Questions on Microbiological Control for a Detox Foot Patch OEM in 2026
The Gel Is Not Sterile: Twelve Questions on Microbiological Control for a Detox Foot Patch OEM in 2026

A gel patch is not a sterile product, and the clause that says so is short: 21 CFR 211.113(a) requires appropriate written procedures designed to prevent objectionable microorganisms in drug products that are not required to be sterile.
A warning letter issued on 9 April 2026 shows what happens when that clause is not met in practice, and it shows it in a way that is difficult to argue with. A firm used an unvalidated treatment protocol on filled drug product batches in an attempt to reduce microbiological content. The laboratory had reported gross contamination on the plates, with two lots too numerous to count for both the total aerobic count and the total yeast and mold count. The firm then released product on the basis of resampling after that treatment.
The corrective action, as the letter records it, included revising the drug product formulation to increase preservative content. The agency addressed that directly and said that preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms, and cannot be relied on to reduce in-process bioburden during manufacturing.
For a detox foot OEM whose matrix is a water-based gel, that sentence is the whole article. The twelve questions below are what the clause looks like when it is applied to a product like this one.
1. Is a gel patch a sterile product?
No, and the question decides which set of rules applies to it.
The distinction in the framework is between a product required to be sterile and a product that is not, and 21 CFR 211.113(a) applies the second category. It requires appropriate written procedures designed to prevent objectionable microorganisms.
| The product | The regime | What it means |
|---|---|---|
| A product required to be sterile | Sterility procedures, and the sterilization validation that goes with them | The microbial question is largely settled by the process |
| A product not required to be sterile | 21 CFR 211.113(a) procedures designed to prevent objectionable microorganisms | The microbial question is continuous and has to be managed throughout manufacturing |
The third row of the second column is the one a gel manufacturer has to sit with. There is no sterilisation step to inherit the microbiological outcome from, so the outcome is whatever the process and the water and the packaging produce.
A detox foot patch OEM that has a water-based gel matrix is manufacturing a non-sterile drug product, and the clause that governs it is the one the letter in this article is about.

2. What does objectionable mean in practice?
It means the organisms that would not be acceptable in the product, and the letter shows that the agency expects the manufacturer to know which ones those are.
Two of the five requirements in that letter are about naming them. The firm has to provide appropriate microbiological batch release specifications for each of its drug products, meaning total counts and identification of bioburden to detect objectionable microbes, and it has to investigate whether additional bacterial species were present beyond the one it had already attributed the contamination to.
| What the letter asks for | Why it matters |
|---|---|
| Total counts | A count tells a manufacturer there is a problem; it does not tell it what the problem is |
| Identification of the bioburden | Without identification, a manufacturer cannot distinguish an organism that is acceptable from one that is not |
| Whether additional bacterial species were present | The letter found a claim that growth on the yeast and mold plates was solely bacterial and asked for evidence supporting it, which was not provided |
| A limit for each product | A single limit applied to every product is a default, not a specification |
The fourth row is the one that changes the work. A limit set for one product is not a limit for another, and the letter asks for the limits to be set per product.
A detox foot patch OEM that has one microbiological specification applied to every product in the catalogue has not written four specifications, and a detox foot patch OEM that has one per product has written the ones the letter asks for.

3. What does a failing microbiological result mean for the batch?
It means the batch cannot be released on the strength of a second test, and the letter is unusually direct about that.
The firm released drug products based on results from resampling after the treatment. The agency did not accept that, and it asked for complete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result, whether or not the result was later invalidated.
| The question | Why it is the right question |
|---|---|
| Can the failing result be invalidated? | A result that is set aside without an investigation has not been answered, it has been deleted |
| Does the investigation cover the system and not only the batch? | The letter records an investigation that attributed the contamination to a component and did not consider out-of-limit recoveries from the water system |
| Does it cover every product where the treatment was attempted? | The response risk assessment covered two failing lots and did not extend to all the products in question |
| Is there a defined action when the answer is a failure? | The letter asks for corrective actions including notifying customers and initiating recalls |
The third row is the one that makes this a management question rather than a laboratory one. A detox foot patch OEM that has treated a failing batch once has learned the procedure; a detox foot patch OEM that has done it without asking which products else it applies to has created a question it cannot scope.

4. Can a preservative solve it?
No, and this is the sentence in the letter that should be read twice.
The agency states that preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating drug products, and cannot be relied on to reduce in-process bioburden during manufacturing.
| What a manufacturer might say | What the letter establishes |
|---|---|
| We increased the preservative content | The letter records that as the corrective action and rejects it as a substitute for controlling contamination |
| The formula is now more resistant | The contamination came from the water system and the process, and a formula change does not address either |
| The batches will now pass | The letter asks for the design and control of the system to be assessed, not for a pass rate |
The third row is the important one. The remedy the letter asks for is upstream, in the water system and the process design, and a formula change is downstream of both.
For a detox foot patch OEM this is the single most useful thing in the case, because the instinct when a micro result fails is to look at the formula first. The letter says that instinct points the wrong way.

5. What has to be assessed in the water system?
Seven characteristics and a count limit, and the list is specific enough to be used as a checklist.
The letter requires a comprehensive remediation plan for the design, control and maintenance of the system, and a comprehensive evaluation of the vulnerabilities of the system design and control, summarising all deficiencies found.
| The characteristic the letter names | The question behind it |
|---|---|
| System temperature | Is the system held at a temperature that does not support the organisms of concern |
| Materials of construction | Does the material in contact with the water support or inhibit growth, and does it degrade |
| Slope | Is the drainable part of the system actually drainable, or does it hold a film |
| Identified dead-legs | Where are the sections of pipe with no flow, and how long are they |
| Stagnant locations | Where does the water sit still, including inside the equipment it feeds |
| Unsanitary fittings | Which connections cannot be cleaned and are not designed to be |
| Flow velocity | Is the velocity high enough to keep the system from becoming a culture vessel |
| Total microbiological count limits | The limits used to monitor whether the system is producing water suitable for the intended uses of each product |
The eighth row is the one that ties the system to the product. A count limit that is right for one product is not automatically right for another, and the letter asks for the limits to be set against the intended uses of each product rather than for the system as a whole.
A detox foot patch OEM that has this list documented has answered the letter, and one that has a water specification and a sanitation schedule has answered a different and much narrower question.

6. What do out-of-trend results mean?
They are in scope, and including them is one of the five requirements.
The letter asks for a summary of results from testing retain samples of all drug product batches that received failing, out-of-specification, out-of-limit or out-of-trend microbiological test results, and also for retain test results from periods when the water system was not operating under a state of control.
| The category | What it is | Why the letter includes it |
|---|---|---|
| Failing | A result outside the specification | The obvious case |
| Out of specification | A result outside the established specification in a qualified method | The formal category, and the one a quality system is built to define |
| Out of limit | A result outside the limit for a material or a system | The letter records an investigation that failed to consider these |
| Out of trend | A result inside the limit but moving in one direction | The category that catches a system drifting before it fails |
| Periods when the system was not in a state of control | A window of time rather than a batch | A system can be out of control while every individual batch passes |
The fourth row is the one that distinguishes a mature programme. An out-of-trend result is a result that passed, and it is the only one of the four that a system which waits for failures will ever see.
The fifth row is the one that is hardest to produce and the most useful, because it answers a question no batch record can: what happened during the periods when things were not right.
For a detox foot patch OEM the four categories together are the difference between a microbiology programme that reacts and one that sees, and the fifth row is the one that most programmes cannot produce at all.

7. What has to be in the investigation?
A root cause, not an attribution, and the letter shows the difference.
The firm investigated the failing results and concluded that the contamination was from a component, recovered from a mixture of that component with another. The letter records that the investigation failed to consider out-of-limit microbiological recoveries from the water system.
| What an attribution looks like | What a root cause looks like |
|---|---|
| Naming where the organism was recovered | Explaining how it got there and why the controls did not stop it |
| Testing one material | Testing the system, the process, the personnel and the materials together |
| Concluding and moving on | Concluding, and then changing the system so that the same thing cannot happen again |
| Leaving the system outside the scope | The letter asks for an evaluation of the system design and control covering seven named characteristics |
The third row of the first column is the pattern the letter was written to stop. A conclusion that identifies a material is a conclusion that lets a system stay exactly as it was.
A detox foot patch OEM whose investigation can explain why a control did not work has a root cause, and a detox foot patch OEM whose investigation identifies a bottle has a place to store the blame.

8. What does the risk assessment have to cover?
Every affected product and every lot still within expiry, not the lots that happened to fail.
The letter requires a detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination, with the actions to be taken specified, such as customer notifications and product recalls, and a further risk assessment on the potential effects of the observed system failures on the quality of all drug product lots currently within expiry.
| The scope | Why the letter insists on it |
|---|---|
| All products where the treatment was attempted | The response covered only the failing lots and did not extend to the others |
| All lots currently within expiry | The lots that were not tested are still on shelves and still in the market |
| The system failures as a cause | A lot-by-lot risk assessment that ignores the system will be wrong in the same way every time |
| The actions, named | Customer notification and recall are named as examples, which means they are expected rather than optional |
The second row is the one that catches a manufacturer by surprise. A firm that investigates the failing lots and stops there has answered a question about three batches when the question was about everything in expiry.
For a detox foot patch OEM the actionable version is simple and expensive: the number of lots in expiry is knowable in advance, and a firm that cannot state it cannot scope a recall either.

9. What this means for a water-based gel patch
The clauses in this letter were written for a manufacturer of prescription and over-the-counter topical products, and the question worth asking is whether they transfer to a cosmetic route. The answer is that most of them do not, and one of them does.
| The requirement | Does it transfer to a cosmetic gel patch | Why |
|---|---|---|
| 21 CFR 211.113(a), procedures to prevent objectionable microorganisms | Not as written, because it sits in the drug framework | A cosmetic route is governed by the cosmetic framework and its own microbiological requirements, and the clause does not apply to it directly |
| A microbiological batch release specification with bioburden identification | Yes, as a matter of commercial practice | A customer asking about microbial quality will ask for identification and not only for a count, whatever the route |
| A water system vulnerability assessment | Yes, and it is the one that matters most | It is a description of the physical plant, and a plant does not change because the regulatory route has changed |
| A retain testing summary across four result categories | Yes, as a matter of customer expectation | It answers the question a customer asks when a micro result surprises them |
| A risk assessment covering every lot within expiry | Yes, for the same reason | A recall is a commercial event regardless of which framework requires it |
The third row is the one worth sitting with. A water system does not know which regulation its output is sold under, and the seven characteristics the letter names are properties of the plant rather than of the paperwork.
For a detox foot patch OEM the practical consequence is that a plant built for the cosmetic route can still be sold a pharmaceutical customer, and the reverse is not true, and the seven questions in section five are the cheapest way to find out which kind of plant a site is.
A detox foot patch OEM that has answered them has a plant description that satisfies both routes, and that is worth more than a cosmetic certificate, because it is the document that answers a question in either market. A detox foot patch OEM that has not answered them has a certificate, and a certificate is what the letter in this article was written about. A detox foot patch OEM that has answered them can answer a pharmaceutical customer on the plant and a cosmetic customer on the specification, and a detox foot patch OEM that cannot has to answer the second in the first place.
About KONGDY Medical


Henan Kongdy Medical Devices Co., LTD. (KONGDY) was founded in 1989 and has 37 years of production experience as of 2026 across pain relief patches, slimming patches, capsicum plasters, heat patches, cooling gel patches, detox foot patches, steam eye masks, mosquito repellent patches and nose strips. Headquartered in Henan, China, KONGDY operates a 100,000-class GMP workshop built in 2008 and obtained ISO 13485 medical device Quality Management System European Standard Certification in 2014. The company runs OEM and ODM services for international brands across multiple regulatory pathways.
For a 2026 procurement evaluation the qualification team can supply the ISO 13485 certificate, GMP workshop audit reports, stability programme documentation, and reference customer case studies upon request via our contact page.
Frequently asked questions
Does the gel in a patch have to be sterile?
No. A product not required to be sterile falls under 21 CFR 211.113(a), which requires appropriate written procedures designed to prevent objectionable microorganisms. A water-based gel matrix is in that category, and the microbial outcome is produced by the process, the water and the packaging rather than by a sterilisation step.
Can increasing the preservative content fix a failing result?
The agency says no, and says it in terms. Preservatives are not a substitute for a comprehensive approach to preventing objectionable microorganisms from contaminating drug products, and cannot be relied on to reduce in-process bioburden during manufacturing. A formula change is not the remedy for contamination that arrived through the water system.
What is a too numerous to count result?
It is a count beyond the range the plate method can enumerate, which is why it cannot be converted into a number and why it cannot be compared against a limit. In the case in this library two lots were too numerous to count for both the total aerobic count and the total yeast and mold count, and the third lot was countable only for the yeast and mold count.
What does out of trend mean and why is it in scope?
It means a result inside the specification but moving consistently in one direction, and it is in scope because it is the category a system shows while it is drifting, before any batch fails. The letter asks for retain testing summaries covering failing, out-of-specification, out-of-limit and out-of-trend results, and also for retain results from periods when the water system was not in a state of control.
What has to be assessed in the water system?
The letter names seven characteristics: system temperature, materials of construction, slope, identified dead-legs, stagnant locations, unsanitary fittings and flow velocity. It also asks for the total microbiological count limits used to monitor whether the system is producing water suitable for the intended uses of each product.
Does the letter require a recall?
It requires a risk assessment with the actions specified, and gives customer notification and product recall as examples of those actions, and it requires complete investigations into all batches with potential objectionable microbiological contamination or a failing microbiological result whether or not the result was later invalidated. In the case in this library the firm itself issued a voluntary recall of lots due to microbiological contamination.
What is the difference between the two findings in this article?
One is that the firm released product on the basis of resampling after an unvalidated treatment on filled batches whose plates had shown gross contamination. The other is that its investigation attributed the contamination to a component and did not consider out-of-limit recoveries from the water system. The first is a decision about a batch and the second is a decision about a scope, and the second is the one that let the first repeat.
What should a supplier be asked for?
The microbiological batch release specification for the product, with the identification requirement rather than the count alone; the retain testing summary across the four categories; the water system vulnerability assessment against the seven named characteristics; and the written procedures that govern all of it. A detox foot patch OEM that can produce those four documents has answered the question, and one that has a water specification and a sanitation schedule has answered a narrower one.
Related Guides
Five further references from the KONGDY knowledge base:
- Cooling Gel Patch OEM: the glycerin and DEG questions
- Heat Patch OEM: twelve questions on third-party release testing
- Frequently asked compliance questions
- KONGWY OEM and ODM manufacturing services
- Slimming Patch OEM: nine stages of an FDA site inspection
